Skip to main content

Advertisement

SpringerLink
Log in

Identification of ribosomal protein L9 as a novel regulator of proinflammatory damage-associated molecular pattern molecules

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

We previously reported that advanced glycation endproducts (AGEs) increase the proinflammatory activity of high mobility group box-1 (HMGB1), a representative damage-associated molecular pattern molecule (DAMP), through their direct interaction. This suggested that AGEs activate other DAMPs and led us to search for novel DAMPs capable of interacting with AGEs.

Methods and results

The chromatographic analysis using AGE-immobilized gel revealed the ribosomal protein family to be a factor with binding activity to AGEs. Ribosomal protein L9 (RPL9), a member of the ribosomal protein family, was found in the centrifugal supernatant of ruptured cells and in the serum of lipopolysaccharide (LPS)-stimulated sepsis model mice, exhibiting similar characteristic properties to HMGB1. Although HMGB1 potentiated LPS-stimulated TNF-α expression in macrophage-like RAW264.7 cells, RPL9 hardly exhibited this activity. Of note, RPL9 significantly suppressed the potentiated mRNA expression and protein production of TNF-α by HMGB1 plus LPS stimulation, suggesting its regulatory roles in DAMP-induced proinflammatory activity. Based on the differential scanning fluorimetric analysis, the direct interaction between RPL9 and HMGB1 may play a role in the suppressive effects of RPL9.

Conclusions

This study suggested that RPL9 is a novel type of DAMP with a regulatory role in the proinflammatory response and provided insight into the pathophysiology of inflammatory diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability

Not applicable.

References

  1. Roh JS, Sohn DH (2018) Damage-associated molecular patterns in inflammatory diseases. Immune Netw 18:e27. https://doi.org/10.4110/in.2018.18.e27

    Article  PubMed  PubMed Central  Google Scholar 

  2. Murao A, Aziz M, Wang H, Brenner M, Wang P (2021) Release mechanisms of major DAMPs. Apoptosis 26:152–162. https://doi.org/10.1007/s10495-021-01663-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Watanabe M, Toyomura T, Tomiyama M, Wake H, Liu K, Teshigawara K, Takahashi H, Nishibori M, Mori S (2020) Advanced glycation end products (AGEs) synergistically potentiated the proinflammatory action of lipopolysaccharide (LPS) and high mobility group box-1 (HMGB1) through their direct interactions. Mol Biol Rep 47:7153–7159. https://doi.org/10.1007/s11033-020-05783-y

    Article  CAS  PubMed  Google Scholar 

  4. Aso Y, Inukai T, Tayama K, Takemura Y (2000) Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 37:87–92

    Article  CAS  PubMed  Google Scholar 

  5. Kanauchi M, Tsujimoto N, Hashimoto T (2001) Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 24:1620–1623

    Article  CAS  PubMed  Google Scholar 

  6. Li S-Y, Du M, Dolence EK, Fang CX, Mayer GE, Ceylan-Isik AF, LaCour KH, Yang X, Wilbert CJ, Sreejayan N, Ren J (2005) Aging induces cardiac diastolic dysfunction, oxidative stress, accumulation of advanced glycation endproducts and protein modification. Aging Cell 4:57–64

    Article  CAS  PubMed  Google Scholar 

  7. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 32:763–777

    Article  CAS  PubMed  Google Scholar 

  8. Reynaert NL, Gopal P, Rutten EPA, Wouters EFM, Schalkwijk CG (2016) Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. Int J Biochem Cell Biol 81:403–418

    Article  CAS  PubMed  Google Scholar 

  9. Watanabe M, Toyomura T, Wake H, Liu K, Teshigawara K, Takahashi H, Nishibori M, Mori S (2017) Advanced glycation end products attenuate the function of tumor necrosis factor-like weak inducer of apoptosis to regulate the inflammatory response. Mol Cell Biochem 434:153–162

    Article  CAS  PubMed  Google Scholar 

  10. Vivoli M, Novak HR, Littlechild JA, Harmer NJ (2014) Determination of protein-ligand interactions using differential scanning fluorimetry. J Vis Exp 91:e51809. https://doi.org/10.3791/51809

    Article  CAS  Google Scholar 

  11. Watanabe M, Toyomura T, Mori S (2021) Application of differential scanning fluorimetry for analyzing molecular interactions: a model study on the interaction between glutathione S-transferase and glutathione, Shujitsu. Univ. J Pharm Sci 8:85–91

    Google Scholar 

  12. Hreggvidsdottir HS, Östberg T, Wähämaa H, Schierbeck H, Aveberger A-C, Klevenvall L, Palmblad K, Ottosson L, Andersson U, Harris HE (2009) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 86:655–662

    Article  CAS  PubMed  Google Scholar 

  13. Hreggvidsdóttir HS, Lundberg AM, Aveberger A-C, Klevenvall L, Andersson U, Harris HE (2012) High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med 18:224–230

    Article  PubMed  Google Scholar 

  14. Taylor DJ, Devkota B, Huang AD, Topf M, Narayanan E, Sali A, Harvey SC, Frank J (2009) Comprehensive molecular structure of the eukaryotic ribosome. Structure 17:1591–1604. https://doi.org/10.1016/j.str.2009.09.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Brodersen DE, Nissen P (2005) The social life of ribosomal proteins. FEBS J 272:2098–2108. https://doi.org/10.1111/j.1742-4658.2005.04651.x

    Article  CAS  PubMed  Google Scholar 

  16. Baik IH, Jo G-H, Seo D, Ko MJ, Cho CH, Lee MG, Lee Y-H (2016) Knockdown of RPL9 expression inhibits colorectal carcinoma growth via the inactivation of Id-1/NF-κB signaling axis. Int J Oncol 49:1953–1962. https://doi.org/10.3892/ijo.2016.3688

    Article  CAS  PubMed  Google Scholar 

  17. Yang J, Zhang P, Wang L (2016) Gene network for identifying the entropy changes of different modules in pediatric sepsis. Cell Physiol Biochem 40:1153–1162. https://doi.org/10.1159/000453169

    Article  CAS  PubMed  Google Scholar 

  18. Wang H, Ward MF, Sama AE (2014) Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets 18:257–268. https://doi.org/10.1517/14728222.2014.863876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kang J-W, Kim S-J, Cho H-I, Lee S-M (2015) DAMPs activating innate immune responses in sepsis. Ageing Res Rev 24:54–65. https://doi.org/10.1016/j.arr.2015.03.003

    Article  CAS  PubMed  Google Scholar 

  20. Gavins FNE, Hickey MJ (2012) Annexin A1 and the regulation of innate and adaptive immunity. Front Immunol 3:354. https://doi.org/10.3389/fimmu.2012.00354

    Article  PubMed  PubMed Central  Google Scholar 

  21. Halder SK, Matsunaga H, Ishii KJ, Ueda H (2015) Prothymosin-alpha preconditioning activates TLR4-TRIF signaling to induce protection of ischemic retina. J Neurochem 135:1161–1177. https://doi.org/10.1111/jnc.13356

    Article  CAS  PubMed  Google Scholar 

  22. Hangai S, Ao T, Kimura Y, Matsuki K, Kawamura T, Negishi H, Nishio J, Kodama T, Taniguchi T, Yanai H (2016) PGE2 induced in and released by dying cells functions as an inhibitory DAMP. Proc Natl Acad Sci U S A 113:3844–3849. https://doi.org/10.1073/pnas.1602023113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Land WG (2020) Use of DAMPs and SAMPs as therapeutic targets or therapeutics: a note of caution. Mol Diagn Ther. https://doi.org/10.1007/s40291-020-00460-z

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by JSPS KAKENHI Grant Numbers 21K06657 and 21K06701, the Kurita Water and Environment Foundation, the Sanyo Broadcasting Foundation, and the Wesco Scientific Promotion Foundation.

Funding

JSPS KAKENHI Grant Numbers 21K06657 and 21K06701, the Kurita Water and Environment Foundation, the Sanyo Broadcasting Foundation, and the Wesco Scientific Promotion Foundation.

Author information

Authors and Affiliations

  1. Department of Pharmacology, School of Pharmacy, Shujitsu University, 1-6-1 Nishigawara, Naka-Ku, Okayama, 703-8516, Japan

    Masahiro Watanabe, Takao Toyomura & Shuji Mori

  2. Department of Pharmacology, Faculty of Medicine, Kindai University, Osaka-Sayama, 589-8511, Japan

    Hidenori Wake, Takashi Nishinaka, Omer Faruk Hatipoglu & Hideo Takahashi

  3. Department of Pharmacology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, 700-8558, Japan

    Masahiro Nishibori

Authors
  1. Masahiro Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takao Toyomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hidenori Wake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Nishinaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Omer Faruk Hatipoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideo Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiro Nishibori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuji Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuji Mori.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest associated with this manuscript.

Ethical approval

Experiments using mice were approved by the animal care committee of Shujitsu University (No. 035–002).

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 105 KB)

Supplementary file2 (PDF 124 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Watanabe, M., Toyomura, T., Wake, H. et al. Identification of ribosomal protein L9 as a novel regulator of proinflammatory damage-associated molecular pattern molecules. Mol Biol Rep 49, 2831–2838 (2022). https://doi.org/10.1007/s11033-021-07096-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-021-07096-0

Keywords

Search

Navigation